Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License
10:17am, Tuesday, 09'th Jun 2020NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License
10:15am, Tuesday, 09'th Jun 2020
SHELTON, CT / ACCESSWIRE / June 9, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines pl
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 8)
Biohaven Pharmaceutical...
Global Coronavirus Vaccine Market: Trends, Forecast & Opportunities (2019-2025) - ResearchAndMarkets.com
12:00am, Wednesday, 03'rd Jun 2020
The
The
SHELTON, CT / ACCESSWIRE / May 26, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines p
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering; 1.4M Shares At $7.30 Per Share
12:31pm, Thursday, 21'st May 2020NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering
12:30pm, Thursday, 21'st May 2020
SHELTON, CT / ACCESSWIRE / May 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines p
Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis
01:51pm, Wednesday, 20'th May 2020Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
10:15am, Wednesday, 20'th May 2020
SHELTON, CT / ACCESSWIRE / May 20, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines pl
